Precipio (NASDAQ:PRPO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Precipio (NASDAQ:PRPO) to a hold rating in a research report report published on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Precipio has an average rating of “Sell”.

Precipio Stock Up 4.3%

Precipio stock opened at $23.39 on Friday. Precipio has a 12 month low of $3.90 and a 12 month high of $28.50. The stock has a fifty day simple moving average of $23.57 and a two-hundred day simple moving average of $20.57. The company has a current ratio of 1.27, a quick ratio of 1.10 and a debt-to-equity ratio of 0.06. The firm has a market cap of $40.93 million, a price-to-earnings ratio of -28.52 and a beta of 1.20.

Precipio (NASDAQ:PRPO) last released its quarterly earnings data on Friday, November 14th. The biotechnology company reported ($0.05) EPS for the quarter. Precipio had a negative net margin of 5.50% and a negative return on equity of 10.07%. The business had revenue of $6.77 million for the quarter.

Hedge Funds Weigh In On Precipio

Institutional investors have recently made changes to their positions in the business. AMH Equity Ltd increased its holdings in Precipio by 370.1% during the third quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock valued at $2,332,000 after buying an additional 103,210 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Precipio by 10.7% during the 4th quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after acquiring an additional 1,400 shares during the period. Geode Capital Management LLC increased its stake in shares of Precipio by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 789 shares in the last quarter. Susquehanna International Group LLP purchased a new stake in shares of Precipio in the 3rd quarter worth $194,000. Finally, Topline Capital Management LLC bought a new position in Precipio in the 3rd quarter worth $1,158,000. Institutional investors own 10.45% of the company’s stock.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.